2021;12:p694284
Ludvik B, Giorgino F, Jdar E, Frias JP, Fernndez Land L, Brown K, et al
2 Sclafani describes the calculus behind that hesitation from the employer's perspective: "I pay for all the people that use a GLP-1 now, and as a self-insured employer, I pay for that dollar for dollar." The return on that spending, he says, is uncertain and likely delayed "I may not see the benefits of these for five, ten, fifteen years" in part because "there's been no long-term rate studies" yet proving newer GLP-1s reduce cardiovascular events
GHKs strong antioxidant and anti-inflammatory activity and ability to control post-injury oxidative damage has led to strong research interest in its use to help subjects recover from tissue injury [1, 6]
Peroxiredoxin 6 overexpression attenuates lipopolysaccharide-induced acute kidney injury